Engflag

Dextromethorphan HBr

Quick links to important sections

Dextromethorphan HBr

Dextromethorphan HBr_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dextromethorphan HBr

What is Dextromethorphan HBr?

Dextromethorphan hydrobromide (HBr) is a synthetic derivative of morphine and a common active ingredient found in numerous over-the-counter cough medications. While it is chemically related to opioids, it does not possess the analgesic or sedative properties typically associated with that class of drugs when used at standard levels.

Mechanism of Action

Dextromethorphan HBr acts primarily as an antitussive, or cough suppressant. It works by targeting the cough center in the medulla oblongata of the brain. By elevating the threshold for coughing, it reduces the urge to cough without inhibiting the movement of the cilia or the clearing of mucus from the respiratory tract.

Chemical Composition

The "HBr" in Dextromethorphan HBr stands for hydrobromide, which is the salt form of the drug. This formulation is used to improve the stability and solubility of the compound in liquid and solid medicinal formats. In the body, the substance is metabolized into dextrorphan, which also contributes to its cough-suppressant effects.

Use in Modern Medicine

Dextromethorphan HBr is utilized to provide temporary relief from a non-productive (dry) cough. This type of cough is often associated with the common cold, the flu, or minor throat and bronchial irritation. Because it focuses on suppressing the cough reflex rather than treating the underlying cause of the irritation, it is classified as a symptomatic treatment.

Regulatory References

  1. NIH Drug Dictionary
  2. NIH StatPearls
  3. NIH MedlinePlus

What side effects are possible with Dextromethorphan HBr?

Possible Side Effects and Safety Information: Dextromethorphan HBr

Dextromethorphan Hydrobromide (Dextromethorphan HBr) is generally well-tolerated when used at recommended doses to temporarily relieve cough caused by the common cold and other upper respiratory infections. However, like any medication, it carries a risk of side effects and requires adherence to specific safety guidelines.

Common Side Effects

Side effects are usually mild and temporary. They are more likely to occur with higher doses or misuse.

System Common Side Effects
Central Nervous System Drowsiness, dizziness, sedation
Gastrointestinal Nausea, vomiting, stomach discomfort

Serious Warnings and Drug Interactions

Serotonin Syndrome: Dextromethorphan HBr can increase the risk of a rare, potentially life-threatening condition called serotonin syndrome, especially when taken with other serotonergic drugs. Do not use this medication if you are currently taking a Monoamine Oxidase Inhibitor (MAOI) or within 14 days of stopping an MAOI, as this is a high-risk combination.

Contraindications: This medication should be used with caution, or avoided, in patients with chronic respiratory conditions, such as emphysema or asthma, where cough is productive and vital for clearing the airways. It is also contraindicated in individuals with a known hypersensitivity to the drug.

Overdose Risk: Misuse or taking doses significantly higher than recommended can lead to serious central nervous system effects, including hallucinations, confusion, and depressed breathing. Keep all medicines out of the reach of children. Consult a healthcare professional immediately if an overdose is suspected.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdose with Dextromethorphan HBr is officially documented in regulatory sources to present primarily with central nervous system (CNS) and autonomic disturbances. Documented manifestations include symptoms such as somnolence, confusion, excitability, delirium, nystagmus (involuntary eye movements), and ataxia. Autonomic signs like tachycardia, muscle rigidity, hypertonia, and diaphoresis (sweating) are also officially listed in overdose profiles. Gastrointestinal effects such as nausea and vomiting may occur.

Regulatory labeling documents the risk of severe, potentially life-threatening outcomes, including Serotonin Syndrome, which may manifest as altered mental status, autonomic instability, and neuromuscular changes. Severe overdose can also result in respiratory depression, seizures, or coma.

When to Seek Urgent Medical Help

It is mandatory to seek immediate medical attention upon suspicion of an overdose. Contact emergency services immediately if severe symptoms are observed, including loss of consciousness, convulsions, respiratory compromise, or signs consistent with Serotonin Syndrome. Regulatory guidance notes that children and adolescents may be susceptible to a greater severity of CNS effects.

Management is defined as symptomatic and supportive treatment, often requiring hospital monitoring and observation for at least six hours. While no specific antidote is officially listed, procedures such as activated charcoal administration may be considered, and specific agents may be used to manage acute CNS effects.

Therapeutic Uses of Dextromethorphan HBr

What Dextromethorphan HBr treats: main uses and benefits

Dextromethorphan HBr is a medication providing symptomatic support for specific clusters of symptoms, applied across distinct therapeutic domains to ease patient discomfort and functional strain. It is commonly used to help with the symptomatic management of cough associated with acute conditions like the common cold, influenza, or minor irritative states. This medication plays a role in managing symptoms related to irritative states in the throat and bronchial airways.

Therapeutic Symptom Management

The primary focus is relevant for easing the frequent, irritating urge to cough that is non-productive (without phlegm). This is applied in scenarios where additional management of discomfort is required, providing support that helps ease the overall symptom burden and helps improve day-to-day comfort during symptomatic periods. It is commonly used to help with the frequency of the persistent cough, which supports patients during difficult episodes and may assist with maintaining functional stability, particularly related to rest.

“This symptomatic support is relevant in contexts where cough symptoms are disruptive or interfere with daily functioning and rest.”

Dextromethorphan HBr may be part of symptomatic management in fixed-dose combination formulations relevant for easing the heightened, sudden, and involuntary episodes associated with Pseudobulbar Affect in certain neurological disorders.

Quick Fact: Relief for Non-Productive Cough

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dextromethorphan HBr?

Eligibility for Dextromethorphan HBr (DM) is strictly defined by regulatory bodies based on age, concurrent medication use, and pre-existing conditions.

Contraindicated Populations

DM is contraindicated and must not be used by individuals with a known hypersensitivity to dextromethorphan or any of its components.

The most critical prohibition is the concurrent use of DM with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy, due to the severe risk of Serotonin Syndrome.

Age and Physiological Restrictions

Category Regulatory Status Restriction Details
Age Restriction Contraindicated/Not Recommended Children under 4 years of age must not use DM (common for most non-prescription formulations). Some international labels extend this restriction to ages 6 or 12.
Chronic Cough Not Recommended Individuals with a chronic or persistent cough (e.g., from smoking, asthma, or emphysema) or a cough producing excessive phlegm should only use DM under medical advice.
Pregnancy/Lactation Ask a Health Professional Use is cautioned, and should be restricted to when the potential benefit outweighs the possible risk.

Condition-Based Caution

Patients with severe hepatic (liver) impairment or severe renal (kidney) impairment should seek professional guidance before using Dextromethorphan due to its metabolism and excretion pathway.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Dextromethorphan HBr primarily through effects on drug metabolism and central nervous system (CNS) activity.

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited due to the risk of Serotonin Syndrome, a restriction that includes a mandatory separation period requiring Dextromethorphan HBr not be used within 14 days of discontinuing an MAOI. The official labeling also identifies a contraindication for co-use with CYP2D6-metabolized drugs that are known to prolong the QT interval.

Pharmacokinetic and Pharmacodynamic Interactions

The primary pharmacokinetic interaction involves the CYP2D6 enzyme system, which metabolizes Dextromethorphan. Co-administration with potent CYP2D6 inhibitors (e.g., Quinidine, Fluoxetine, Bupropion) is documented to significantly increase Dextromethorphan plasma concentrations and exposure due to reduced metabolic clearance. This risk is also relevant for individuals identified as CYP2D6 Poor Metabolizers.

From a pharmacodynamic perspective, use with other serotonergic agents (including certain antidepressants and the herbal product St. John's wort) may result in additive effects, increasing the risk of Serotonin Syndrome. Furthermore, concurrent use with CNS depressants, including alcohol, may cause additive depressant effects, as described in official product information.

Mechanism of Action

Dextromethorphan HBr functions as a centrally acting agent that modulates the cough reflex arc within the central nervous system. The compound primarily exerts its action as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically within the medullary cough center. Antagonism of the NMDA receptor interrupts the excitatory glutamatergic signaling cascade in this region. This interaction results in the modulation of the medullary cough center's activity, thereby diminishing the transmission of neural impulses responsible for triggering the cough reflex. Additionally, Dextromethorphan HBr exhibits an affinity for the sigma1 receptor, where its agonism contributes to the overall suppression of cough signaling. The cumulative effect of NMDA receptor antagonism and sigma1 receptor agonism is the central suppression of the cough reflex through altered afferent signaling sensitivity.

Dosage and Administration Information

How to Use Dextromethorphan HBr

Administration of Dextromethorphan HBr, the non-opioid antitussive, is governed by official regulatory instructions focused entirely on the oral route for its various formulations. The approach for using this medication is strictly defined by established dosing limits and fixed time intervals, rather than by individual preference or ad-hoc adjustments.

Official Dosing and Frequency

Feature Official Instruction Summary
Route of administration Oral route exclusively.
Standard Dose (Adults/12+ years) Immediate-Release (IR) forms are typically dosed at 10 mg to 30 mg per dose.
Frequency Schedule Administration must maintain fixed intervals, such as every 4 to 8 hours for IR formulations or every 12 hours for extended-release suspensions.
Maximum Daily Ceiling The use protocol specifies an absolute upper limit of 120 mg per 24 hours for the adult population, which must not be exceeded.

Procedural Administration Constraints

The usage protocol is characterized by several specific conditions that ensure proper kinetic delivery. The medication may be taken with or without food. However, liquid formulations necessitate the use of a specific measuring device (e.g., a dosing cup or spoon) to administer the dose accurately.

Extended-release (ER) preparations, such as tablets or suspensions, possess a critical administration constraint: they must be swallowed whole and must not be crushed, chewed, or otherwise modified, as this would compromise the time-release mechanism.

Duration and Age-Specific Use

The use of Dextromethorphan HBr is generally intended for short-term use, with regulatory constraints often specifying that the duration should not typically exceed seven days. Dosing guidelines also mandate specific adjustments for age groups; for instance, the administration to children under four years is generally not recommended in the context of over-the-counter labels, while those between 6 and 12 years require a specific reduced dosage.

Recent Clinical Evidence

Dextromethorphan HBr: Recent Clinical Evidence

Dextromethorphan HBr (DXM) is widely recognized as an over-the-counter antitussive, or cough suppressant, approved for the temporary relief of coughs associated with minor throat and bronchial irritation. While its primary role is antitussive, recent clinical evidence and regulatory approvals have expanded the scope of its recognized therapeutic use, particularly when combined with agents that inhibit its rapid metabolism.

Approved Combination Therapy Indications
Pseudobulbar Affect (PBA)
Major Depressive Disorder (MDD)

Emerging Research Areas

The most significant recent evidence has focused on the use of DXM in combination therapies for neurological and psychiatric conditions, utilizing its mechanism as an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist.

  • Major Depressive Disorder (MDD): The United States Food and Drug Administration (FDA) has approved a combination of dextromethorphan/bupropion as a rapid-acting treatment for adults with MDD. Clinical trials for this combination have explored effects on depression and anxiety indices.
  • Pseudobulbar Affect (PBA): A combination of dextromethorphan/quinidine is approved for treating PBA, a neurological condition characterized by uncontrollable episodes of crying or laughing. In this formulation, quinidine serves to increase the circulating concentration of DXM by inhibiting its metabolism.
  • Pain and Other Indications: Ongoing and completed studies continue to investigate DXM for potential use in treating various pain conditions, including postoperative pain and fibromyalgia. Other exploratory research is examining its effects in areas such as traumatic brain injury and refractory seizures, although evidence in these areas remains limited or mixed.

Frequently Asked Questions (FAQ)

Common questions about Dextromethorphan HBr (FAQ)

Q: Can I stop taking Hypothetamine once I feel better?

It is generally recommended not to suddenly stop taking Hypothetamine without professional guidance. Abruptly stopping this medication may lead to withdrawal symptoms, which can sometimes be severe, and it may also lead to a return or worsening of the original condition.

Consultation with a healthcare provider is recommended to develop a plan for safely reducing the dose over time, if necessary.

Q: Does Hypothetamine interact with alcohol?

Yes, official label information advises against the use of alcohol while taking Hypothetamine. Alcohol may increase the severity of certain drug side effects, such as dizziness and drowsiness, and could potentially reduce the medication's intended action.

Avoiding alcohol is generally recommended due to the potential for compounded side effects.

Q: How long does it take for Hypothetamine to start working?

The onset of action can vary among individuals. Some individuals may begin to notice effects within two weeks, but achieving the full therapeutic effect may require consistent use for at least four to six weeks.

Hypothetamine is considered a slow-acting medication for some conditions. It is important to follow your healthcare provider’s instructions regarding the duration of treatment.

How should Dextromethorphan HBr be stored and disposed of?

Official Storage and Disposal Guidelines

Storage and disposal requirements for Dextromethorphan HBr are strictly defined in regulatory documents to maintain drug stability and ensure safety.

Storage Condition Requirement
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed. Protect from light and excessive heat or moisture.
Child Safety Keep out of reach of children at all times, placing it in a secure location out of their sight.

For disposal, the primary method is using a designated drug take-back program or mail-back service. If a take-back option is unavailable, the medicine should be mixed with an unappealing substance (like dirt or used coffee grounds), sealed in a plastic bag, and placed in the household trash. This measure helps prevent contamination and unintentional ingestion. The medication must not be allowed to reach the ground water or sewage system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dextromethorphan HBr found in:

A-Z Index: